Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.

NCT Number	NCT06024772
Lead Sponsor	Thomas Jefferson University Collaborators: Amsterdam UMC, location VUmc, Eindhoven University of Technology, Eigen, GE Healthcare
Conditions	Prostate Carcinoma
Enrollment	300 participants
Start Date	2026-07
Primary Completion	2026-08-01 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-05